☰

Sabrina Lusvarghi, Ph.D. - Publications

Affiliations: 
2009 Carnegie Mellon University, Pittsburgh, PA 
Area:
Organic Chemistry, Biochemistry
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Yang Y, Wu ZX, Wang JQ, Teng QX, Lei ZN, Lusvarghi S, Ambudkar SV, Chen ZS, Yang DH. OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology. 12: 620874. PMID 33658942 DOI: 10.3389/fphar.2021.620874  0.337
2021 Kita DH, Guragossian N, Zattoni IF, Moure VR, Rego FGM, Lusvarghi S, Moulenat T, Belhani B, Picheth G, Bouacida S, Bouaziz Z, Marminon C, Berredjem M, Jose J, Gonçalves MB, et al. Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles. Scientific Reports. 11: 1788. PMID 33469044 DOI: 10.1038/s41598-020-79892-w  0.32
2020 Sajid A, Lusvarghi S, Murakami M, Chufan EE, Abel B, Gottesman MM, Durell SR, Ambudkar SV. Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein. Proceedings of the National Academy of Sciences of the United States of America. PMID 33168729 DOI: 10.1073/pnas.2016270117  0.317
2020 Ashar YV, Zhou J, Gupta P, Teng QX, Lei ZN, Reznik SE, Lusvarghi S, Wurpel J, Ambudkar SV, Chen ZS. BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers. 12. PMID 32899268 DOI: 10.3390/Cancers12092502  0.412
2020 Wu CP, Hung CY, Lusvarghi S, Huang YH, Tseng PJ, Hung TH, Yu JS, Ambudkar SV. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology. 114137. PMID 32634436 DOI: 10.1016/J.Bcp.2020.114137  0.424
2020 Yang Y, Ji N, Teng QX, Cai CY, Wang JQ, Wu ZX, Lei ZN, Lusvarghi S, Ambudkar SV, Chen ZS. Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells . Frontiers in Oncology. 10: 700. PMID 32477943 DOI: 10.3389/Fonc.2020.00700  0.427
2020 Wu CP, Lusvarghi S, Hsiao SH, Liu TC, Li YQ, Huang YH, Hung TH, Ambudkar SV. Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products. PMID 32347726 DOI: 10.1021/Acs.Jnatprod.9B01022  0.409
2020 Wu CP, Lusvarghi S, Tseng PJ, Hsiao SH, Huang YH, Hung TH, Ambudkar SV. MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. American Journal of Cancer Research. 10: 164-178. PMID 32064159  0.321
2020 Lusvarghi S, Robey RW, Gottesman MM, Ambudkar SV. Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. F1000research. 9. PMID 32055397 DOI: 10.12688/F1000Research.21295.1  0.383
2020 Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS. Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers. 12. PMID 31940916 DOI: 10.3390/Cancers12010186  0.404
2019 Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. International Journal of Molecular Sciences. 21. PMID 31905792 DOI: 10.3390/Ijms21010238  0.424
2019 Lusvarghi S, Ambudkar SV. ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators. The Biochemical Journal. PMID 31774117 DOI: 10.1042/Bcj20190736  0.406
2019 Sava GP, Fan H, Fisher RA, Lusvarghi S, Pancholi S, Ambudkar SV, Martin LA, Charles Coombes R, Buluwela L, Ali S. ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942. Oncogene. PMID 31530935 DOI: 10.1038/S41388-019-1008-Y  0.353
2019 Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. PMID 31515284 DOI: 10.1124/Mol.119.115964  0.383
2019 Sajid A, Raju N, Lusvarghi S, Vahedi S, Swenson RE, Ambudkar SV. Synthesis and characterization of Bodipy-FL-cyclosporine A as a substrate for multidrug resistance-linked P-glycoprotein (ABCB1). Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 31371421 DOI: 10.1124/Dmd.119.087734  0.411
2019 Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV. Avapritinib, a selective inhibitor of KIT and PDGFRα reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines. Molecular Pharmaceutics. PMID 31117741 DOI: 10.1021/Acs.Molpharmaceut.9B00274  0.425
2019 Nandigama K, Lusvarghi S, Shukla S, Ambudkar SV. Large-scale purification of functional human P-glycoprotein (ABCB1). Protein Expression and Purification. PMID 30851394 DOI: 10.1016/J.Pep.2019.03.002  0.386
2019 Hsiao SH, Lusvarghi S, Huang YH, Ambudkar SV, Hsu SC, Wu CP. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer Letters. PMID 30639533 DOI: 10.1016/J.Canlet.2019.01.001  0.38
2019 Murakami M, Chufan EE, Lusvarghi S, Ambudkar SV. Abstract 1270: Human P-glycoprotein-mediated drug transport: Two aromatic residues in the drug-binding pocket are critical for function Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1270  0.39
2018 Sajid A, Lusvarghi S, Chufan EE, Ambudkar SV. Evidence for the critical role of transmembrane helices 1 and 7 in substrate transport by human P-glycoprotein (ABCB1). Plos One. 13: e0204693. PMID 30265721 DOI: 10.1371/Journal.Pone.0204693  0.401
2018 Vahedi S, Lusvarghi S, Pluchino K, Shafrir Y, Durell SR, Gottesman MM, Ambudkar SV. Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein. Scientific Reports. 8: 12716. PMID 30143707 DOI: 10.1038/S41598-018-30984-8  0.398
2018 Lusvarghi S, Ghirlando R, Davison JR, Bewley CA. Chemical and Biophysical Approaches for Complete Characterization of Lectin-Carbohydrate Interactions. Methods in Enzymology. 598: 3-35. PMID 29306440 DOI: 10.1016/Bs.Mie.2017.06.010  0.315
2016 Lusvarghi S, Bewley CA. Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses. 8. PMID 27783038 DOI: 10.3390/V8100296  0.363
2016 Lusvarghi S, Lohith KM, Morin-Leisk J, Ghirlando R, Hinshaw JE, Bewley CA. Binding site geometry and subdomain valency control effects of neutralizing lectins on HIV-1 viral particles. Acs Infectious Diseases. PMID 27669574 DOI: 10.1021/Acsinfecdis.6B00139  0.399
2016 Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, Nguyen R, O'Dell S, Lusvarghi S, Bewley CA, Li H, Shaw GM, Sheng Z, Shapiro L, Wyatt R, et al. Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. Plos Pathogens. 12: e1005537. PMID 27064278 DOI: 10.1371/Journal.Ppat.1005537  0.358
2016 Dogo-Isonagie C, Lee SL, Lohith K, Liu H, Mandadapu SR, Lusvarghi S, O'Connor RD, Bewley CA. Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry. Bioorganic & Medicinal Chemistry. PMID 26968647 DOI: 10.1016/J.Bmc.2016.02.044  0.348
2016 Rausch JW, Sztuba-Solinska J, Lusvarghi S, Le Grice SF. Novel Biochemical Tools for Probing HIV RNA Structure. Methods in Molecular Biology (Clifton, N.J.). 1354: 91-117. PMID 26714707 DOI: 10.1007/978-1-4939-3046-3_7  0.321
2015 Lusvarghi S, Ghirlando R, Wong CH, Bewley CA. Glycopeptide mimetics recapitulate high-mannose-type oligosaccharide binding and function. Angewandte Chemie (International Ed. in English). 54: 5603-8. PMID 25776945 DOI: 10.1002/Anie.201500157  0.376
2015 Acharya P, Lusvarghi S, Bewley CA, Kwong PD. HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Expert Opinion On Therapeutic Targets. 19: 765-83. PMID 25724219 DOI: 10.1517/14728222.2015.1010513  0.331
2013 Lusvarghi S, Sztuba-Solinska J, Purzycka KJ, Pauly GT, Rausch JW, Grice SF. The HIV-2 Rev-response element: determining secondary structure and defining folding intermediates. Nucleic Acids Research. 41: 6637-49. PMID 23640333 DOI: 10.1093/Nar/Gkt353  0.335
2013 Purzycka KJ, Legiewicz M, Matsuda E, Eizentstat LD, Lusvarghi S, Saha A, Le Grice SF, Garfinkel DJ. Exploring Ty1 retrotransposon RNA structure within virus-like particles. Nucleic Acids Research. 41: 463-73. PMID 23093595 DOI: 10.1093/Nar/Gks983  0.322
2009 Lusvarghi S, Murphy CT, Roy S, Tanious FA, Sacui I, Wilson WD, Ly DH, Armitage BA. Loop and backbone modifications of peptide nucleic acid improve g-quadruplex binding selectivity. Journal of the American Chemical Society. 131: 18415-24. PMID 19947597 DOI: 10.1021/Ja907250J  0.589
2009 Lusvarghi S, Kim JM, Creeger Y, Armitage BA. Refined multivalent display of bacterial spore-binding peptides. Organic & Biomolecular Chemistry. 7: 1815-20. PMID 19590776 DOI: 10.1039/B820013K  0.546
Show low-probability matches.